{"id":"kn035-plus-gemcitabine-oxaliplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"KN035 is a humanized monoclonal antibody targeting PD-L1 that prevents tumor cells from evading immune surveillance by blocking the PD-L1/PD-1 axis. When combined with gemcitabine (a nucleoside analog) and oxaliplatin (a platinum-based chemotherapy), the regimen aims to synergistically enhance anti-tumor immunity through both direct chemotherapy cytotoxicity and immune checkpoint blockade. This combination approach targets multiple mechanisms of tumor growth and immune evasion.","oneSentence":"KN035 is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with gemcitabine and oxaliplatin chemotherapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:03.574Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic pancreatic cancer (in combination with gemcitabine and oxaliplatin)"},{"name":"Advanced biliary tract cancer (in combination with gemcitabine and oxaliplatin)"}]},"trialDetails":[{"nctId":"NCT03478488","phase":"PHASE3","title":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC","status":"ACTIVE_NOT_RECRUITING","sponsor":"3D Medicines (Sichuan) Co., Ltd.","startDate":"2018-04-16","conditions":"Biliary Tract Neoplasms","enrollment":480}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Experimental"],"phase":"phase_3","status":"active","brandName":"KN035 plus Gemcitabine & oxaliplatin","genericName":"KN035 plus Gemcitabine & oxaliplatin","companyName":"3D Medicines (Sichuan) Co., Ltd.","companyId":"3d-medicines-sichuan-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KN035 is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with gemcitabine and oxaliplatin chemotherapy. Used for Metastatic pancreatic cancer (in combination with gemcitabine and oxaliplatin), Advanced biliary tract cancer (in combination with gemcitabine and oxaliplatin).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}